Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis
Tofacitinib and baricitinib are the first orally available, small-molecule inhibitors of JAK enzymes to be approved for the treatment of RA. Tofacitinib is a selective JAK1,3 inhibitor with less activity against JAK2 and TYK2 and baricitinib a selective, oral JAK1,2 inhibitor with moderate activity...
| Main Author: | |
|---|---|
| Format: | Journal article |
| Published: |
Oxford University Press
2019
|